Amneal Pharmaceuticals, Inc. (AMRX) stock
AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3062% above fair value
$21.23−0.15 (-0.70%)
Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –
Amneal Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Amneal Pharmaceuticals's total debt was $2.57B at Jun 30, 2026. For fiscal 2025 it was $2.57B, up 7.8% from the year before. The highest annual figure on record is $2.78B in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.57B | +7.8% |
| FY2024 | Dec 31, 2024 | $2.39B | -1.4% |
| FY2023 | Dec 31, 2023 | $2.42B | -7.7% |
| FY2022 | Dec 31, 2022 | $2.62B | -3.3% |
| FY2021 | Dec 31, 2021 | $2.71B | -2.5% |
| FY2020 | Dec 31, 2020 | $2.78B | +5.7% |
| FY2019 | Dec 31, 2019 | $2.63B | -0.8% |
| FY2018 | Dec 31, 2018 | $2.65B | +83.6% |
| FY2017 | Dec 31, 2017 | $1.44B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.57B | +18.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.57B | +17.7% |
| Q4 FY2025 | Dec 31, 2025 | $2.57B | +7.8% |
| Q3 FY2025 | Sep 30, 2025 | $2.57B | +7.5% |
| Q2 FY2025 | Jun 30, 2025 | $2.18B | -9.4% |
| Q1 FY2025 | Mar 31, 2025 | $2.19B | -9.4% |
| Q4 FY2024 | Dec 31, 2024 | $2.39B | -1.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.39B | -6.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.40B | -6.9% |
| Q1 FY2024 | Mar 31, 2024 | $2.41B | -7.0% |
| Q4 FY2023 | Dec 31, 2023 | $2.42B | -7.7% |
| Q3 FY2023 | Sep 30, 2023 | $2.57B | -2.5% |
| Q2 FY2023 | Jun 30, 2023 | $2.58B | -2.7% |
| Q1 FY2023 | Mar 31, 2023 | $2.59B | -4.1% |
| Q4 FY2022 | Dec 31, 2022 | $2.62B | -3.3% |
| Q3 FY2022 | Sep 30, 2022 | $2.64B | -3.0% |
| Q2 FY2022 | Jun 30, 2022 | $2.65B | -3.6% |
| Q1 FY2022 | Mar 31, 2022 | $2.70B | -2.0% |
| Q4 FY2021 | Dec 31, 2021 | $2.71B | -2.5% |
| Q3 FY2021 | Sep 30, 2021 | $2.72B | -2.5% |
| Q2 FY2021 | Jun 30, 2021 | $2.75B | -1.6% |
| Q1 FY2021 | Mar 31, 2021 | $2.76B | -1.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.78B | +5.7% |
| Q3 FY2020 | Sep 30, 2020 | $2.79B | +5.7% |
| Q2 FY2020 | Jun 30, 2020 | $2.79B | +5.8% |
| Q1 FY2020 | Mar 31, 2020 | $2.80B | +5.9% |
| Q4 FY2019 | Dec 31, 2019 | $2.63B | -0.8% |
| Q3 FY2019 | Sep 30, 2019 | $2.64B | -5.8% |
| Q2 FY2019 | Jun 30, 2019 | $2.64B | -0.0% |
| Q1 FY2019 | Mar 31, 2019 | $2.65B | +83.2% |
| Q4 FY2018 | Dec 31, 2018 | $2.65B | – |
| Q3 FY2018 | Sep 30, 2018 | $2.80B | – |
| Q2 FY2018 | Jun 30, 2018 | $2.64B | – |
| Q4 FY2017 | Dec 31, 2017 | $1.44B | – |
See a number that looks wrong?